Boston Scientific Corp (BSX)vsHyperfine Inc (HYPR)
BSX
Boston Scientific Corp
$44.33
+2.86%
HEALTHCARE · Cap: $69.50B
HYPR
Hyperfine Inc
$1.47
-8.00%
HEALTHCARE · Cap: $158.83M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 134377% more annual revenue ($20.61B vs $15.33M). BSX leads profitability with a 17.3% profit margin vs -226.9%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
HYPR
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-18.7%
Fair Value
$37.36
Current Price
$44.33
$6.97 premium
Intrinsic value data unavailable for HYPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Revenue surging 82.6% year-over-year
Areas to Watch
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -101.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth. Revenue growth of 82.6% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
BSX profiles as a mature stock while HYPR is a hypergrowth play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.42 — expect wider price swings.
HYPR is growing revenue faster at 82.6% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 23/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a leading medical technology innovator that has revolutionized imaging diagnostics with the introduction of the first FDA-cleared portable MRI system. This groundbreaking solution enhances accessibility to imaging directly at the point of care, thereby improving patient outcomes and expediting clinical decision-making. By prioritizing cost efficiency and convenience, Hyperfine is well-positioned to capitalize on burgeoning market opportunities, making it an appealing investment for institutional investors interested in transformative healthcare advancements.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?